Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.35), $0.05 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $14.8 million versus the consensus estimate of $15.87 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.